Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)

Autor: John K. Erban, B Adesunloye, Christopher R. Chitambar, S Badve, T Lee, I Shalaby, V Canfield, C Ma, M Radovich, Elisavet Paplomata, KD Miller, R Nanda, M Graham, L Aggarwal, D Bruetman, M Lippman, N Radhakrishnan, M Danso, Carla I. Falkson, Michael A. Thompson, R Langdon, Bryan J. Schneider, M McCormick, NA Reddy, B O'Neil, K Daily, Marcelo Blaya, Radhika Walling, Filipa Lynce, E Robin, P Helft

Publikováno v: Cancer Research. 77:OT3-04

Background: About 1/3 of patients with TNBC who receive preoperative therapy will experience a pathological complete response (pCR). Patients with residual disease have a markedly inferior overall survival (OS) compared to those who experience pCR. R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe935099d33eb6279e0e11bcd4e91757
https://doi.org/10.1158/1538-7445.sabcs16-ot3-04-01

The diagnosis of low-grade peripheral B-cell neoplasms in bone marrow trephines

Autor: Francesco Pezzella, PJ Munson, Ah Goldstone, KD Miller, K C Gatter

Publikováno v: British Journal of Haematology. 108:369-376

The aim of this study was to establish how effective is the use of immunohistochemistry on formalin-fixed bone marrow in diagnosing low-grade B-cell neoplasms. We investigated a series of 41 consecutive patients with bone marrow involvement for whom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11c45f40d2d8c14ed9b6e322af015d35
https://doi.org/10.1046/j.1365-2141.2000.01844.x

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Autor: Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan., Powderly J; Carolina BioOncology Institute, Huntersville, NC, United States., Abdul Razak A; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada., LoRusso P; Yale Cancer Center, Yale University, New Haven, CT, United States., Miller KD; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Kao S; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Kongpachith S; AbbVie Bay Area, South San Francisco, CA, United States., Tribouley C; AbbVie Bay Area, South San Francisco, CA, United States., Graham M; AbbVie Bay Area, South San Francisco, CA, United States., Stoll B; AbbVie Bay Area, South San Francisco, CA, United States., Patel M; AbbVie Bay Area, South San Francisco, CA, United States., Sahtout M; AbbVie Bay Area, South San Francisco, CA, United States., Blaney M; AbbVie Bay Area, South San Francisco, CA, United States., Leibman R; AbbVie Bay Area, South San Francisco, CA, United States., Golan T; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.; Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel., Tolcher A; New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2024 Oct 29; Vol. 14, pp. 1376551. Date of Electronic Publication: 2024 Oct 29 (Print Publication: 2024).

ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in Cancer.

Autor: Stojanovic L; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.; Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Abbotts R; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.; Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Tripathi K; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.; Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Coon CM; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA., Rajendran S; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA., Farid EA; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA., Hostetter G; Van Andel Research Institute, Grand Rapids, MI 49503, USA., Guarnieri JW; Center for Mitochondrial and Epigenomic Medicine, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA., Wallace DC; Center for Mitochondrial and Epigenomic Medicine, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.; Department of Pediatrics, Division of Human Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Liu S; Department of Medical and Molecular Genetics, Indiana University School of Medicine Indianapolis, IN 46202, USA.; Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine Indianapolis, IN 46202, USA., Wan J; Department of Medical and Molecular Genetics, Indiana University School of Medicine Indianapolis, IN 46202, USA.; Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine Indianapolis, IN 46202, USA., Calendo G; Coriell Institute for Medical Research, Camden, NJ 08103., Marker R; Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Gohari Z; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.; Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA., Inayatullah MMA; University of Southern Denmark, Odense, Denmark., Tiwari VK; University of Southern Denmark, Odense, Denmark., Kader T; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Santagata S; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Drapkin R; Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.; Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA., Kommoss S; Diakonie-Klinikum Schwäbisch Hall, Germany, Institute for Health Informatics.; Kliniken Essen-Mitte, Gynäkologie und Gynäkologische Onkologie, Germany., Pfisterer J; Department of Medicine, David Geffen School of Medicine., Konecny GE; University of California Los Angeles, Los Angeles, CA., Coopergard R; Institute for Health Informatics, University of Minnesota, Minneapolis, MN 55455, USA., Issa JP; Coriell Institute for Medical Research, Camden, NJ 08103., Winterhoff BJN; Department of Obstetrics, Gynecology and Women's Health (OBGYN), Division of Gynecologic Oncology, University of Minnesota, MN 55812-3011, USA., Topper MJ; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA., Sandusky GE; Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, IN 46202, USA., Baylin SB; Diakonie-Klinikum Schwäbisch Hall, Germany, Institute for Health Informatics.; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA., Nephew KP; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA.; Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine Indianapolis, IN 46202, USA.; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN 46202, USA., Rassool FV; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.; Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Oct 21. Date of Electronic Publication: 2024 Oct 21.

ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.

Autor: Schneider BP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Zhao F; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Ballinger TJ; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Garcia SF; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Shen F; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Virani S; Aurora Cancer Care-Southern Lakes VLCC, Burlington, WI., Cella D; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Bales C; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Jiang G; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Hayes L; Pink-4-Ever Ending Disparities, Indianapolis, IN., Miller N; Pink-4-Ever Ending Disparities, Indianapolis, IN., Srinivasiah J; Georgia NCORP, Decatur, GA., Stringer-Reasor EM; University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL., Chitalia A; MedStar Washington Hospital Center, Washington, DC., Davis AA; Washington University School of Medicine, St Louis, MO., Makower DF; Montefiore Medical Center-Weiler Hospital, New York, NY., Incorvati J; Fox Chase Comprehensive Cancer Center, Philadelphia, PA., Simon MA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, PA.; Deceased, Baltimore, MD., DeMichele A; University of Pennsylvania, Philadelphia, PA., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Sparano JA; Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY., Wagner LI; University of North Carolina, Chapel Hill, NC., Wolff AC; Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 20; Vol. 42 (24), pp. 2899-2907. Date of Electronic Publication: 2024 Jun 03.